Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 9/20 | 0.43 |
| ▸ | PTGES | O14684 | 8/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 8/20 | 0.43 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15470449 | 0.83 | TLR7 (0.45) | CTSKPPARGPTGESALOX5PSEN1 | |
| SCHEMBL15469737 | 0.83 | TLR7 (0.45) | CTSKPPARGPTGESALOX5PSEN1 | |
| SCHEMBL21769263 | 0.83 | TLR7 (0.45) | CTSKPPARGPTGESALOX5PSEN1 | |
| SCHEMBL21769268 | 0.79 | KCNH2 (0.42) | CTSKPPARGPTGESALOX5TRPC6 | |
| SCHEMBL21769215 | 0.71 | CTSK (0.41) | CTSKPPARGPTGESALOX5CNR2 | |
| SCHEMBL9824716 | 0.69 | HDAC1 (0.55) | ALOX5 | |
| SCHEMBL18265443 | 0.69 | TAS1R3 (0.46) | CNR2 | |
| SCHEMBL15469717 | 0.69 | BRD4 (0.42) | CTSKPTGESALOX5 | |
| SCHEMBL19269033 | 0.68 | SIGMAR1 (0.44) | CTSKPPARGPTGESALOX5SIGMAR1 | |
| SCHEMBL6249902 | 0.68 | CTSK (0.62) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541050-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2023-01-03 | — | — | US | disclosed |
| US-20210023082-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541050-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | CTSK 3614/4885PPARG 1216/4885PTGES 2402/4885 |
| US-20210023082-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | CTSK 3614/4885PPARG 1216/4885PTGES 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.